Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
Safety profile presented at ASN Kidney Week 2026 across 29 autoimmune patients treated with a single dose of FT819 and fludarabine-free, less-intensive conditioning continues to be favorable, further supporting RECLAIM-LN
Covered in this story
Call it yourself
No calls on $FATE yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Fate Therapeutics Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.